FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100. A total of 41 filers reported holding FENNEC PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,962,569 | -41.9% | 321,206 | +5.8% | 0.00% | – |
| Q1 2024 | $3,375,131 | +13.2% | 303,519 | +14.3% | 0.00% | – |
| Q4 2023 | $2,980,593 | +51.8% | 265,650 | +1.6% | 0.00% | – |
| Q3 2023 | $1,963,369 | -15.0% | 261,434 | -0.0% | 0.00% | – |
| Q2 2023 | $2,308,913 | +13.6% | 261,485 | -20.1% | 0.00% | – |
| Q1 2021 | $2,032,000 | -20.0% | 327,151 | -4.1% | 0.00% | – |
| Q4 2020 | $2,541,000 | +27.7% | 341,051 | +3.9% | 0.00% | – |
| Q3 2020 | $1,990,000 | -15.5% | 328,306 | +16.5% | 0.00% | – |
| Q2 2020 | $2,354,000 | +189.9% | 281,868 | +68.4% | 0.00% | – |
| Q1 2019 | $812,000 | -21.4% | 167,372 | +3.4% | 0.00% | – |
| Q4 2018 | $1,033,000 | -19.2% | 161,918 | +4.0% | 0.00% | – |
| Q3 2018 | $1,278,000 | -17.5% | 155,725 | +5.0% | 0.00% | – |
| Q2 2018 | $1,549,000 | – | 148,325 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 630,000 | $3,056,000 | 0.85% |
| Southpoint Capital Advisors LP | 3,997,214 | $19,386,000 | 0.82% |
| 683 Capital Management, LLC | 971,351 | $4,711,000 | 0.43% |
| Avoro Capital Advisors LLC | 1,105,999 | $5,364,000 | 0.23% |
| Eventide Asset Management | 720,000 | $3,492,000 | 0.12% |
| Granahan Investment Management | 410,932 | $1,993,000 | 0.11% |
| Zebra Capital Management LLC | 17,568 | $85,000 | 0.04% |
| Hartford Financial Management Inc. | 12,300 | $60,000 | 0.02% |
| OXFORD ASSET MANAGEMENT LLP | 84,750 | $411,000 | 0.01% |
| Wealthspire Advisors, L.P. | 9,500 | $46,000 | 0.00% |